Home › Companies › Avidity Biosciences, Inc. › 2025-2026
Download data (CSV): ballot items · votes by manager · column guide.
Compiled from SEC Form N-PX filings and Avidity Biosciences, Inc.’s Form 8-K, filed February 26, 2026 (Item 5.07 on EDGAR). Page generated November 20, 2026.
Meeting of February 26, 2026: 2 items on Avidity Biosciences, Inc.’s Form 8-K, filed February 26, 2026: 2 approved.
Notable dissent: 1 other board item (17.6% against).
Dissent tiers, on the company’s own Form 8-K tally (support = FOR ÷ (FOR + AGAINST), or FOR ÷ (FOR + WITHHELD) on a withhold ballot; abstentions and broker non-votes excluded): shareholder proposals with 15% support or more are notable, 25% significant, 40% high; director nominees with 10% or more against or withheld are notable, 20% significant; say-on-pay under 80% support is notable, under 70% significant; equity and compensation plans with 15% or more against are notable, 25% significant; any other item the board put forward with 15% or more against is notable. How this is decided
Explore Avidity Biosciences, Inc. in the interactive database Compare manager voting policies
These tallies are Avidity Biosciences, Inc.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed February 26, 2026 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.
| Ballot item | For | Against | Abstain | Withheld | Broker non-votes | Support (of votes cast) | Reported outcome | Voting standard |
|---|---|---|---|---|---|---|---|---|
| 1. The Transactions Proposal To adopt (i) the Agreement and Plan of Merger, dated as of October 25, 2025 (the " Merger Agreement "), among Novartis AG, a company limited by shares ( Aktiengesellschaft ) incorporated under the laws of Switzerland (" Novartis " | 123,351,048 | 8,090 | 60,331 | -- | 296,100 | 99.9% | Approved | — |
| 3. Non-Binding Merger-Related Compensation Proposal To approve, on a non-binding, advisory basis, the compensation that may be paid or become payable to the Company's named executive officers in connection with the transactions contemplated by the Merger A | 101,383,553 | 21,654,186 | 381,730 | -- | 296,100 | 82% | Approved | — |
Source: Avidity Biosciences, Inc., Form 8-K, filed with the SEC on February 26, 2026 — read the filing on EDGAR.
See voting trends for Health Care companies, 2025-2026: shareholder support by sector and by company size.
274 asset managers disclosed a vote on at least one Avidity Biosciences, Inc. item in their SEC Form N-PX filings. Each item below shows how many of them voted on it, and how. Share totals are the shares those managers' funds voted, summed across every fund they report. These are reported items, not a count of the ballot: fund filings describe one ballot item in different words. Two descriptions are shown as one item only on evidence — the same text (or one cut short of the other), the same director nominee, or a match to the same row of Avidity Biosciences, Inc.’s own Form 8-K tally — never because they merely read alike. A description that could not be joined that way is listed on its own, so one ballot item can appear more than once.
Combines 4 wordings of this item as funds reported it.
99.9% Approved · of votes cast
Description as filed by funds: To adopt (i) the Agreement and Plan of Merger, dated as of October 25, 2025 (the "Merger Agreement"), among Novartis AG, a company limited by shares (Aktiengesellschaft) incorporated under the laws of Switzerland ("Novartis"), Ajax Acquisition Sub, Inc., a Delaware corporation and an indirect wholly owned subsidiary of Novartis, and Avidity Biosciences, Inc., a Delaware corporation (the "Company"), and (ii) the Separation and Distribution Agreement, dated as of October 25, 2025 (the "Separation Agreement"), among the Company, Bryce Therapeutics, Inc., a newly formed Delaware corporation and wholly owned subsidiary of the Company, and which on December 8, 2025, changed its name to Atrium Therapeutics, Inc., and Novartis (with respect to certain sections therein).
Avidity Biosciences, Inc.’s own tally for this item (“1. The Transactions Proposal To adopt (i) the Agreement and Plan of Merger, dated as of October 25, 2025 (the " Merger Agreement "), among Novartis AG, a company limited by shares ( Aktiengesellschaft ) incorporated unde”): 123,351,048 for, 8,090 against — passed, per its Form 8-K filed February 26, 2026 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “Proposal 1: The Transactions Proposal To adopt (i) the Agreement and Plan of Merger, dated as of October 25, 2025 (the " Merger Agreement "), among Novartis AG, a company limited by shares ( Aktiengesellschaft ) incorporated under the laws of Switzerland (" Novartis " or " Parent "), Ajax Acquisiti…”
Support: 99.9% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 68 asset managers below reported 32,565,486 for, 108 not voted.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 12,406,458 | 0 | 0 | 0 | For |
| BlackRock | 7,185,431 | 0 | 0 | 0 | For |
| Fidelity | 2,956,705 | 0 | 0 | 0 | For |
| JANUS INVESTMENT FUND | 2,396,003 | 0 | 0 | 0 | For |
| State Street | 1,500,037 | 0 | 0 | 0 | For |
| Charles Schwab | 1,179,880 | 0 | 0 | 0 | For |
| MERGER FUND | 978,849 | 0 | 0 | 0 | For |
| NEXPOINT FUNDS I | 890,580 | 0 | 0 | 0 | For |
| MUTUAL FUND SERIES TRUST | 531,219 | 0 | 0 | 0 | For |
| Equitable | 263,025 | 0 | 0 | 0 | For |
| TIAA | 238,916 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 190,491 | 0 | 0 | 0 | For |
| ARBITRAGE FUNDS | 142,238 | 0 | 0 | 0 | For |
| Jackson National | 136,623 | 0 | 0 | 0 | For |
| Lincoln Financial | 105,418 | 0 | 0 | 0 | For |
| Tidal Trust II | 105,336 | 0 | 0 | 0 | For |
| GMO | 90,328 | 0 | 0 | 0 | For |
| Global X | 79,484 | 0 | 0 | 0 | For |
| DWS | 71,673 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 64,815 | 0 | 0 | 0 | For |
| ProShares | 64,797 | 0 | 0 | 0 | For |
| New York Life | 59,918 | 0 | 0 | 0 | For |
| Northern Trust | 58,060 | 0 | 0 | 0 | For |
| John Hancock | 56,782 | 0 | 0 | 0 | For |
| Dunham Funds | 56,181 | 0 | 0 | 0 | For |
Showing the 25 largest of 68 asset managers. All 68 are in the interactive database (link above).
95% of fund votes cast · no official result
Description as filed by funds: To adjourn the Special Meeting, if necessary, desirable or appropriate or to solicit additional proxies if, at the time of the Special Meeting, there are an insufficient number of votes in favor of adopting the Merger Agreement and the Separation Agreement.
The 67 asset managers below reported 30,921,141 for, 1,635,907 against, 8,042 abstained, 108 not voted. The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 12,406,458 | 0 | 0 | 0 | For |
| BlackRock | 7,185,431 | 0 | 0 | 0 | For |
| Fidelity | 2,956,705 | 0 | 0 | 0 | For |
| JANUS INVESTMENT FUND | 2,396,003 | 0 | 0 | 0 | For |
| State Street | 3,699 | 1,496,338 | 0 | 0 | Against |
| Charles Schwab | 1,179,880 | 0 | 0 | 0 | For |
| MERGER FUND | 978,849 | 0 | 0 | 0 | For |
| NEXPOINT FUNDS I | 890,580 | 0 | 0 | 0 | For |
| MUTUAL FUND SERIES TRUST | 531,219 | 0 | 0 | 0 | For |
| Equitable | 263,025 | 0 | 0 | 0 | For |
| TIAA | 238,916 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 190,491 | 0 | 0 | 0 | For |
| ARBITRAGE FUNDS | 142,238 | 0 | 0 | 0 | For |
| Jackson National | 136,623 | 0 | 0 | 0 | For |
| Lincoln Financial | 26,118 | 79,300 | 0 | 0 | Mixed |
| Tidal Trust II | 105,336 | 0 | 0 | 0 | For |
| GMO | 90,328 | 0 | 0 | 0 | For |
| Global X | 79,484 | 0 | 0 | 0 | For |
| DWS | 71,673 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 64,815 | 0 | 0 | 0 | For |
| ProShares | 64,797 | 0 | 0 | 0 | For |
| New York Life | 59,918 | 0 | 0 | 0 | For |
| Northern Trust | 58,060 | 0 | 0 | 0 | For |
| John Hancock | 56,782 | 0 | 0 | 0 | For |
| Dunham Funds | 56,181 | 0 | 0 | 0 | For |
Showing the 25 largest of 67 asset managers. All 67 are in the interactive database (link above).
Combines 6 wordings of this item as funds reported it.
82% Approved · of votes cast
Description as filed by funds: To approve, on a non-binding, advisory basis, the compensation that may be paid or become payable to our named executive officers in connection with the transactions contemplated by the Merger Agreement and the Separation Agreement.
Avidity Biosciences, Inc.’s own tally for this item (“3. The Non-Binding Merger-Related Compensation Proposal To approve, on a non-binding, advisory basis, the compensation that may be paid or become payable to the Company's named executive officers in connection with the t”): 101,383,553 for, 21,654,186 against — passed, per its Form 8-K filed February 26, 2026 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “The following advisory votes were cast at the Special Meeting (in person or by proxy) and the Non-Binding Merger-Related Compensation Proposal was approved:”
Support: 82% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 12,405,407 | 1,051 | 0 | 0 | For |
| BlackRock | 2,035,670 | 5,149,761 | 0 | 0 | Mixed |
| Fidelity | 2,909,539 | 47,166 | 0 | 0 | For |
| JANUS INVESTMENT FUND | 2,396,003 | 0 | 0 | 0 | For |
| State Street | 1,498,337 | 1,700 | 0 | 0 | For |
| Charles Schwab | 1,179,636 | 244 | 0 | 0 | For |
| MERGER FUND | 978,849 | 0 | 0 | 0 | For |
| NEXPOINT FUNDS I | 0 | 890,580 | 0 | 0 | Against |
| MUTUAL FUND SERIES TRUST | 531,219 | 0 | 0 | 0 | For |
| Equitable | 3,500 | 259,525 | 0 | 0 | Against |
| TIAA | 0 | 238,916 | 0 | 0 | Against |
| QUANTITATIVE MASTER SERIES LLC | 0 | 190,491 | 0 | 0 | Against |
| ARBITRAGE FUNDS | 142,238 | 0 | 0 | 0 | For |
| Jackson National | 136,623 | 0 | 0 | 0 | For |
| Lincoln Financial | 105,418 | 0 | 0 | 0 | For |
| Tidal Trust II | 105,336 | 0 | 0 | 0 | For |
| GMO | 90,328 | 0 | 0 | 0 | For |
| Global X | 0 | 79,484 | 0 | 0 | Against |
| DWS | 71,673 | 0 | 0 | 0 | For |
| JPMorgan | 66,864 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 64,815 | 0 | 0 | 0 | For |
| ProShares | 64,797 | 0 | 0 | 0 | For |
| New York Life | 59,918 | 0 | 0 | 0 | For |
| Northern Trust | 58,060 | 0 | 0 | 0 | For |
| John Hancock | 34,389 | 22,393 | 0 | 0 | Mixed |
Fund voting reports, all 67 managers: 25,549,787 for, 7,074,016 against, 8,042 abstained, 108 not voted. Showing the 25 largest; every one is in the interactive database (link above).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Janus Henderson | 11,363,308 | 0 | 0 | 0 | For |
| RA CAPITAL MANAGEMENT, L.P. | 8,641,031 | 0 | 0 | 0 | For |
| Avoro Capital Advisors LLC | 8,515,749 | 0 | 0 | 0 | For |
| OAK RIDGE INVESTMENTS LLC | 5,696,982 | 0 | 0 | 0 | For |
| Pentwater Capital Management LP | 5,696,982 | 0 | 0 | 0 | For |
| BlackRock | 1,148,596 | 4,288,733 | 0 | 0 | Mixed |
| BALYASNY ASSET MANAGEMENT L.P. | 0 | 4,491,544 | 0 | 0 | Against |
| State Street | 3,883,099 | 6,000 | 0 | 0 | For |
| Fiera Capital Corp | 3,521,471 | 0 | 0 | 0 | For |
| FARALLON CAPITAL MANAGEMENT, L.L.C. | 3,233,000 | 0 | 0 | 0 | For |
| GEODE CAPITAL MANAGEMENT, LLC | 3,135,141 | 0 | 0 | 0 | For |
| Fidelity | 225,699 | 2,301,000 | 0 | 0 | Mixed |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 2,502,419 | 0 | 0 | 0 | For |
| GLAZER CAPITAL, LLC | 2,039,716 | 0 | 0 | 0 | For |
| TIG Advisors, LLC | 1,452,833 | 0 | 0 | 0 | For |
| Charles Schwab | 1,187,030 | 244 | 0 | 0 | For |
| Vanguard | 1,129,964 | 0 | 0 | 0 | For |
| Weiss Asset Management LP | 1,079,838 | 0 | 0 | 0 | For |
| Northern Trust | 940,839 | 0 | 0 | 0 | For |
| Goldman Sachs | 845,896 | 0 | 0 | 0 | For |
| AllianceBernstein | 0 | 800,016 | 0 | 0 | Against |
| Gabelli | 626,696 | 0 | 0 | 0 | For |
| Citadel | 574,521 | 0 | 0 | 0 | For |
| Logos Global Management LP | 0 | 500,000 | 0 | 0 | Against |
| MELLON INVESTMENTS Corp | 495,728 | 0 | 0 | 0 | For |
Institutional-manager reports, all 222 managers: 75,613,092 for, 14,919,788 against, 166,332 abstained, 5,021 not voted. Showing the 25 largest; every one is in the interactive database (link above).
100% Fund and manager reports combined; may count the same shares twice · no official result
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice). The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| JPMorgan | 66,864 | 0 | 0 | 0 | For |
Fund voting reports, all 1 managers: 66,864 for.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| HBK INVESTMENTS L P | 2,294,654 | 0 | 0 | 0 | For |
| JPMorgan | 48,279 | 0 | 0 | 0 | For |
| Wilshire Advisors LLC | 40 | 0 | 0 | 0 | For |
| Coyle Financial Counsel LLC | 19 | 0 | 0 | 0 | For |
Institutional-manager reports, all 4 managers: 2,342,992 for.
Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 151,205,000 shares outstanding at the time of that meeting.
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Vanguard | 8.21% |
| 2 | BlackRock | 4.75% |
| 3 | Fidelity | 1.96% |
| 4 | JANUS INVESTMENT FUND | 1.58% |
| 5 | State Street | 0.99% |
| 6 | Charles Schwab | 0.78% |
| 7 | MERGER FUND | 0.65% |
| 8 | NEXPOINT FUNDS I | 0.59% |
| 9 | MUTUAL FUND SERIES TRUST | 0.35% |
| 10 | Equitable | 0.17% |
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Janus Henderson | 7.52% |
| 2 | RA CAPITAL MANAGEMENT, L.P. | 5.71% |
| 3 | Avoro Capital Advisors LLC | 5.63% |
| 4 | OAK RIDGE INVESTMENTS LLC | 3.77% |
| 5 | Pentwater Capital Management LP | 3.77% |
| 6 | BlackRock | 3.60% |
| 7 | BALYASNY ASSET MANAGEMENT L.P. | 2.97% |
| 8 | State Street | 2.57% |
| 9 | Fiera Capital Corp | 2.33% |
| 10 | FARALLON CAPITAL MANAGEMENT, L.L.C. | 2.14% |
As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row gives its source and the date its figure is as of: for Form 13F the quarter end it reports, for Schedules 13D and 13G the filing date, and for the proxy statement the date of its ownership table (or, where that date has not been read, the date the proxy was filed). The rows are therefore not all as of the same day.
| Holder | Shares | % outstanding | Source, as of |
|---|---|---|---|
| Vanguard Group | 13,649,250 | 9.03% | Form 13F, quarter ended March 31, 2026 |
| RTW Investments, LP | 12,079,734 | 7.99% | Proxy statement (DEF 14A), proxy filed April 29, 2025 |
| FMR LLC | 10,404,096 | 6.88% | Proxy statement (DEF 14A), proxy filed April 29, 2025 |
| BlackRock, Inc. | 9,042,979 | 5.98% | Proxy statement (DEF 14A), proxy filed April 29, 2025 |
| Avoro Capital Advisors LLC | 8,515,792 | 5.63% | Schedule 13G, filed February 17, 2026 |
| JANUS HENDERSON GROUP PLC | 6,939,503 | 4.59% | Schedule 13G, filed February 17, 2026 |
| RA Capital Management, L.P. | 6,300,408 | 4.17% | Proxy statement (DEF 14A), proxy filed April 29, 2025 |
| Sarah Boyce | 1,966,740 | 1.30% | Proxy statement (DEF 14A), proxy filed April 29, 2025 |
| Morgan Stanley | 1,092,482 | 0.72% | Form 13F, quarter ended March 31, 2026 |
| Wellington Management Group LLP | 723,118 | 0.48% | Schedule 13G, filed February 10, 2026 |
Percentages above are of 151,205,000 shares outstanding, as reported by Avidity Biosciences, Inc. on its Form 10-K dated December 31, 2025 (see the filing on EDGAR). This is the count contemporaneous with the 2025-2026 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.
At Avidity Biosciences, Inc.'s shareholder meeting held February 26, 2026, in the 2025-2026 proxy season, 274 asset managers reported votes on at least one item in their SEC Form N-PX filings, covering 1,012 separate fund positions. Their filings are grouped here into 4 reported items; because filers word the same ballot item differently, that can be more than the number of items on the ballot. On the most widely held item on that ballot — To approve, on a non-binding, advisory basis, the compensation that may be paid or become… — Avidity Biosciences, Inc.'s filing reports the proposal as approved, with 82% support of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). Source: Avidity Biosciences, Inc.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on February 26, 2026.
Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from Avidity Biosciences, Inc.’s 10-K dated December 31, 2025. This page is a static snapshot rebuilt weekly on November 20, 2026; a live search always shows the current data.
Avidity Biosciences, Inc. proxy season coverage: 2023-2024 · 2024-2025 · 2025-2026 (this page).
Proxy Votes Now, “Avidity Biosciences, Inc. 2026 Special Meeting: Vote Results”, https://proxyvotesnow.com/company/avidity-biosciences-inc/2026 (version of November 20, 2026). Derived from SEC Form N-PX and Form 8-K filings; tables licensed CC BY 4.0. Licence: CC BY 4.0.